AlphaMed Inc. announced that it received a $500,000 two-year STTR Phase II grant award from the National Cancer Institute to further develop a targeted radiotherapy for metastatic melanoma.
Mediterranean Diet May Improve Responses to Immune Checkpoint Blockade for Advanced Melanoma
The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques
Air Pollution from Wildfire Smoke Can Exacerbate Skin Conditions
The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice
Vitamin D Supplements During Pregnancy May Reduce Eczema in Infants
New Technology Could Allow Us to Rethink Alopecia Scores